3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
2
Unknown
1
Suspended
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Stomach Neoplasms
32
Carcinoma, Hepatocellular
23
Carcinoma, Non-Small-Cell Lung
16
Small Cell Lung Carcinoma
11
Ovarian Neoplasms
11
Colorectal Neoplasms
11
Sarcoma
9
Lung Neoplasms
9
Nasopharyngeal Carcinoma
7
Neoplasms
6
Breast Neoplasms
6
Triple Negative Breast Neoplasms
5
Head and Neck Neoplasms
5
Glioma
5
Esophageal Neoplasms
5
Cholangiocarcinoma
5
Recurrence
4
Pancreatic Neoplasms
4
Osteosarcoma
4
Esophageal Squamous Cell Carcinoma
4
Biliary Tract Neoplasms
4
Advanced Gastric Cancer
4
Uterine Cervical Neoplasms
3
Thyroid Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Solid Tumor
3
Neoplasm Metastasis
3
NSCLC
3
Melanoma
3
Gastrointestinal Neoplasms
3
Interventions
Amifostine
4
Cisplatin
3
Voriconazole
2
Radiotherapy
2
Paclitaxel
2
Methotrexate
2
Drug Therapy
2
selinexor
1
sargramostim
1
pazopanib
1
lometrexol
1
icotinib
1
glucarpidase
1
camrelizumab
1
bismuth tripotassium dicitrate
1
apatinib
1
Telbivudine
1
Surgical Procedures, Operative
1
Pregabalin
1
Pharmaceutical Preparations
1
Ofloxacin
1
Nivolumab
1
Metronidazole
1
Levofloxacin
1
Imatinib Mesylate
1
Hyperthermic Intraperitoneal Chemotherapy
1
Gefitinib
1
Folic Acid
1
Etoposide
1
Esomeprazole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Drug-Related Side Effects and Adverse Reactions
×
apatinib
×
Clear all
NCT04351308
2020-05-19
MAPAC
Peking University People's Hospital
Phase 2
Unknown
60 enrolled